Clinical Trial Detail

NCT ID NCT02978443
Title A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Georgetown University
Indications

mucosal melanoma

acral lentiginous melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.